ADC Therapeutics SA (NYSE:ADCT)
$ 2.93 -0.05 (-1.68%) Market Cap: 283.30 Mil Enterprise Value: 112.41 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 46/100

ADC Therapeutics SA Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Transcript

Jun 12, 2020 / 12:30PM GMT
Release Date Price: $40.32 (+4.48%)
Operator

Welcome to the ADC Therapeutics conference call to review the Lonca Phase II and Phase I/II combination clinical trial data presented at EHA today. (Operator Instructions)

I would like now to turn the call over to Amanda Hamilton, Investor Relations at ADC Therapeutics. Please proceed.

Amanda Hamilton
ADC Therapeutics SA - IR Officer

Good morning, and welcome to our call. Earlier this morning, we issued a press release with new clinical data for loncastuximab tesirine, or Lonca, which is now available on the Virtual 25th Congress of the European Hematology Association, or EHA25 website. This release as well as the slides we will present today are available on the Investors section of our website at www.adctherapeutics.com.

A replay of today's call will also be made available on our website. After our prepared remarks, we will open the call for Q&A. As a reminder, during today's call, we will be making forward-looking statements regarding our financial outlook. On

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot